Moderna, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating potential derivative action claims on behalf of shareholders of Moderna, Inc. ("Moderna" or the "Company") (MRNA) against certain of its directors for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

The investigation concerns whether Moderna's board of directors allegedly breached their fiduciary duties to the Company and its shareholders by failing to maintain adequate internal controls and oversight systems.

The focus of the investigation centers on allegations that, since October 25, 2021, Moderna’s board and senior management may have failed to implement and oversee mission-critical safety and compliance systems related to the Company’s COVID-19 vaccine for pediatric use. On September. 12, 2025, Moderna’s stock price fell 6.9% following widespread media reports that Trump-administration health officials intended to present data to a CDC panel linking 25 child deaths to COVID-19 vaccines. This development appeared to directly contradict Moderna’s prior public assurances that “no serious safety concerns” had been identified for pediatric use, raising concerns that the board and officers may have failed to properly monitor, investigate, or disclose potential safety signals.

The investigation will examine whether Moderna’s board and relevant committees, including the Audit and Product & Technology Committees, seemingly failed to ensure robust oversight of pediatric vaccine safety reporting. It further seeks to determine whether officers, including the CEO and Chief Medical Officer, may have knowingly or recklessly issued incomplete or misleading statements regarding pediatric safety, or failed to escalate and address internal or external red flags. The inquiry also considers whether any compensation structures or conflicts of interest may have incentivized the understatement of pediatric safety risks, and whether these alleged governance failures resulted in financial or reputational harm to the Company.

Longterm shareholders who have held Moderna stock continuously may be able to pursue claims on behalf of the Company against responsible directors and officers. A shareholder action could seek to recover damages on behalf of the Company and may result in corporate governance reforms designed to prevent similar misconduct in the future.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.